NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases<
17 Nov 2021

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting<
16 Nov 2021

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

AU-011 may offer patients a safe, effective first-line therapy for early-stage disease that preserves vision.
AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access<
04 Nov 2021

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

His responsibilities include ensuring broad patient access to ilofotase alfa, AM-Pharma’s drug candidate for the treatment of sepsis-associated acute kidney injury, currently in Phase III clinical development.
Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ<
03 Nov 2021

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

Aura Biosciences is the sixth portfolio company of Ysios to be listed on NASDAQ, and the third one this year.
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer<
02 Nov 2021

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer.
Synendos Therapeutics Appoints Scientific Advisory Board<
26 Oct 2021

Synendos Therapeutics Appoints Scientific Advisory Board

Scientific Advisory Board made up of prominent scientists with significant CNS expertise
ONA Therapeutics Strengthens Scientific Leadership Team<
21 Oct 2021

ONA Therapeutics Strengthens Scientific Leadership Team

Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development.
VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001<
21 Oct 2021

VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001

Funding comprises grant financing of up to €2.5 million and up to €15 million in equity investment
CorWave Wins 2021 HealthTech Award<
19 Oct 2021

CorWave Wins 2021 HealthTech Award

CorWave received the Medtech Award, which recognizes a medical device or diagnostic company that has distinguished itself over the past two years.
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors<
18 Oct 2021

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

Mr. Myers will serve as a Class III director, and join both the Compensation and Nominating and Corporate Governance Committee

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.